

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of:

SHAN, et al.

Serial Number: 09/481,572

Filed: January 11, 2000

For: HYPERICIN AND HYPERICIN EXTRACT: SPECIFIC T-TYPE CALCIUM CHANNEL BLOCKER

Atty. Dck. No. 108061-09013

Group Art Unit: 1651

Examiner: Meller, M.

DECLARATION UNDER 37 CFR 1.132

Dear Sir:

I, Dr. Peter K. T. Pang, declare as follows:


1. I am one of the inventors of the above-identified application and am fully familiar with the subject matter thereof, as well as the references relied upon by the Examiner.
2. I understand that the claims in the above-identified application are considered unpatentable over EP 847 756 and over the combination of BE 654914 or DE 1692045 in view of EP 647 756.
3. To the best of my knowledge, the current scientific knowledge is that the diseases claimed in claim 3 of this application have no direct relationship to, and are not considered to be secondary causes of, Hepatitis C infection. Therefore, the mechanism of action as claimed in this application, blocking of T-Type calcium channels, is unrelated to the anti-

RECEIVED  
DEC 27 2001  
TECH CENTER 160012900

viral activity of European Patent No. 847,756; and thus this application should and can be considered as not anticipated by EP 847,746.

4. The undersigned declarant declare further that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true, and further, that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001, of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Signed this 17 day of December, 2001.

  
Dr. Peter K. T. Pang